{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T03:24:24Z","timestamp":1795231464250,"version":"4.10.3"},"reference-count":86,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE:<\/jats:title>\n                    <jats:p>To provide updated evidence-based recommendations for the treatment of postmenopausal osteoporosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TARGET POPULATION:<\/jats:title>\n                    <jats:p>Postmenopausal patients with primary osteoporosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>This guideline was developed using an a priori protocol in conjunction with a writing team consisting of two specialists in obstetrics and gynecology appointed by the ACOG Committee on Clinical Practice Guidelines\u2013Gynecology and one external subject matter expert. ACOG medical librarians completed a comprehensive literature search for primary literature within Cochrane Library, Cochrane Collaboration Registry of Controlled Trials, EMBASE, PubMed, and MEDLINE. Studies that moved forward to the full-text screening stage were assessed by two authors from the writing team based on standardized inclusion and exclusion criteria. Included studies underwent quality assessment, and a modified GRADE (Grading of Recommendations Assessment, Development, and Evaluation) evidence-to-decision framework was applied to interpret and translate the evidence into recommendation statements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RECOMMENDATIONS:<\/jats:title>\n                    <jats:p>This Clinical Practice Guideline includes updated recommendations on who should receive osteoporosis pharmacotherapy, the benefits and risks of available pharmacotherapy options, treatment monitoring and follow-up, and the role of calcium and vitamin D in the management of postmenopausal osteoporosis. Recommendations are classified by strength and evidence quality. Ungraded Good Practice Points are included to provide guidance when a formal recommendation could not be made because of inadequate or nonexistent evidence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000004730","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T14:02:11Z","timestamp":1652709731000},"page":"698-717","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":72,"title":["ACOG Clinical Practice Guideline No. 2: Management of Postmenopausal Osteoporosis"],"prefix":"10.1097","volume":"139","author":[{"name":"ACOG Committee on Clinical Practice Guidelines\u2013Gynecology","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260916","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/M19-0533","article-title":"Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review","volume":"171","author":"Fink","year":"2019","journal-title":"Ann Intern Med"},{"key":"R2-20260916","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025","volume":"22","author":"Burge","year":"2007","journal-title":"J Bone Miner Res"},{"key":"R3-20260916","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/AOG.0000000000004514","article-title":"Osteoporosis prevention, screening, and diagnosis. Clinical Practice Guideline No. 1. American College of Obstetricians and Gynecologists","volume":"138","year":"2021","journal-title":"Obstet Gynecol"},{"key":"R4-20260916","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/AOG.0000000000004519","article-title":"Clinical practice guideline methodology: methodology. American College of Obstetricians and Gynecologists","volume":"138","year":"2021","journal-title":"Obstet Gynecol"},{"key":"R6-20260916","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R7-20260916","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R8-20260916","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jclinepi.2014.12.011","article-title":"Guideline panels should not GRADE good practice statements","volume":"68","author":"Guyatt","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"R10-20260916","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.285.3.320","article-title":"Risk of new vertebral fracture in the year following a fracture","volume":"285","author":"Lindsay","year":"2001","journal-title":"JAMA"},{"key":"R11-20260916","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Clinical Practice Guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R12-20260916","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/archinte.163.17.2052","article-title":"Low frequency of treatment of osteoporosis among postmenopausal women following a fracture","volume":"163","author":"Andrade","year":"2003","journal-title":"Arch Intern Med"},{"key":"R13-20260916","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1089\/jwh.2012.3812","article-title":"Osteoporosis healthcare disparities in postmenopausal women","volume":"21","author":"Hamrick","year":"2012","journal-title":"J Womens Health (Larchmt)"},{"key":"R14-20260916","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1007\/s11606-009-1031-8","article-title":"Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender","volume":"24","author":"Curtis","year":"2009","journal-title":"J Gen Intern Med"},{"key":"R15-20260916","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.amjmed.2017.02.042","article-title":"Osteoporosis in the Women's Health Initiative: another treatment gap?","volume":"130","author":"Sattari","year":"2017","journal-title":"Am J Med"},{"key":"R16-20260916","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1111\/jgs.16455","article-title":"Racial disparities exist in outcomes after major fragility fractures","volume":"68","author":"Wright","year":"2020","journal-title":"J Am Geriatr Soc"},{"key":"R17-20260916","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1097\/AOG.0000000000002459","article-title":"Importance of social determinants of health and cultural awareness in the delivery of reproductive health care. ACOG Committee Opinion No. 729. American College of Obstetricians and Gynecologists","volume":"131","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R19-20260916","doi-asserted-by":"crossref","first-page":"10.1177\/0002764213487340","DOI":"10.1177\/0002764213487340","article-title":"Racism and health I: pathways and scientific evidence","volume":"57","author":"Williams","year":"2013","journal-title":"Am Behav Sci"},{"key":"R20-20260916","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1146\/annurev-publhealth-040218-043750","article-title":"Racism and health: evidence and needed research","volume":"40","author":"Williams","year":"2019","journal-title":"Annu Rev Public Health"},{"key":"R21-20260916","first-page":"265","article-title":"Health care disparities in postmenopausal women referred for DXA screening","volume":"38","author":"Hamrick","year":"2006","journal-title":"Fam Med"},{"key":"R22-20260916","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s11606-007-0217-1","article-title":"Racial and socioeconomic disparities in bone density testing before and after hip fracture","volume":"22","author":"Neuner","year":"2007","journal-title":"J Gen Intern Med"},{"issue":"suppl 1","key":"R24-20260916","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"key":"R25-20260916","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation [published erratum appears in Osteoporos Int 2015;26:2045\u20137]","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"issue":"suppl 3","key":"R26-20260916","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2013.0215","article-title":"NCCN task force report: bone health in cancer care","volume":"11","author":"Gralow","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"R27-20260916","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/GME.0000000000000515","article-title":"Impact of aromatase inhibitor treatment on vertebral morphology and bone mineral density in postmenopausal women with breast cancer","volume":"23","author":"Villa","year":"2016","journal-title":"Menopause"},{"key":"R28-20260916","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10549-019-05464-w","article-title":"Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials","volume":"179","author":"Qian","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"R29-20260916","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.01696","article-title":"Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline","volume":"37","author":"Shapiro","year":"2019","journal-title":"J Clin Oncol"},{"key":"R30-20260916","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2018.6537","article-title":"Screening to prevent osteoporotic fractures: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"319","author":"Viswanathan","year":"2018","journal-title":"JAMA"},{"key":"R31-20260916","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1001\/jama.2018.7498","article-title":"Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement. US Preventive Services Task Force","volume":"319","author":"Curry","year":"2018","journal-title":"JAMA"},{"key":"R32-20260916","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis [published erratum appears in J Clin Endocrinol Metab 2021;106:e1494]","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R33-20260916","doi-asserted-by":"crossref","first-page":"115081","DOI":"10.1016\/j.bone.2019.115081","article-title":"Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: a systematic review and network meta-analysis","volume":"130","author":"Simpson","year":"2020","journal-title":"Bone"},{"key":"R34-20260916","first-page":"2640","article-title":"Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis","volume":"23","author":"Yang","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R35-20260916","doi-asserted-by":"crossref","first-page":"dgaa048","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update","volume":"105","author":"Shoback","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R36-20260916","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijsu.2019.03.004","article-title":"Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: a meta-analysis","volume":"66","author":"Yuan","year":"2019","journal-title":"Int J Surg"},{"key":"R37-20260916","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.maturitas.2019.08.003","article-title":"Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: a systematic review and network meta-analysis of randomized controlled trials","volume":"129","author":"Hernandez","year":"2019","journal-title":"Maturitas"},{"key":"R38-20260916","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1210\/jc.2019-00193","article-title":"Women's values and preferences regarding osteoporosis treatments: a systematic review","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R39-20260916","doi-asserted-by":"crossref","first-page":"841","DOI":"10.4158\/EP161678.RA","article-title":"Clinical evaluation of cost efficacy of drugs for treatment of osteoporosis: a meta-analysis","volume":"23","author":"Albert","year":"2017","journal-title":"Endocr Pract"},{"key":"R40-20260916","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bone.2013.09.023","article-title":"Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review","volume":"58","author":"Eriksen","year":"2014","journal-title":"Bone"},{"key":"R41-20260916","doi-asserted-by":"crossref","first-page":"100729","DOI":"10.1016\/j.bonr.2020.100729","article-title":"Pharmacologic intervention for prevention of fractures in osteopenic and osteoporotic postmenopausal women: systemic review and meta-analysis","volume":"13","author":"Wu","year":"2020","journal-title":"Bone Rep"},{"key":"R42-20260916","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture prevention with zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N Engl J Med"},{"key":"R43-20260916","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00198-007-0493-y","article-title":"Effects of risedronate on fracture risk in postmenopausal women with osteopenia","volume":"19","author":"Siris","year":"2008","journal-title":"Osteoporos Int"},{"key":"R44-20260916","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.clinthera.2019.05.001","article-title":"Real-world adherence and persistence with bisphosphonate therapy in postmenopausal women: a systematic review","volume":"41","author":"Fardellone","year":"2019","journal-title":"Clin Ther"},{"key":"R45-20260916","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00198-009-0930-1","article-title":"Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis","volume":"21","author":"Cott\u00e9","year":"2010","journal-title":"Osteoporos Int"},{"key":"R46-20260916","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research [published erratum appears in J Bone Miner Res 2016;31:1910]","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res"},{"key":"R47-20260916","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1016\/j.jacr.2017.02.018","article-title":"ACR Appropriateness Criteria(\u00ae): osteoporosis and bone mineral density. Expert Panel on Musculoskeletal Imaging","volume":"14","author":"Ward","year":"2017","journal-title":"J Am Coll Radiol"},{"key":"R48-20260916","first-page":"\/j\/hmbci.2019.40.issue-0021","article-title":"Clinical evidence of the effect of bisphosphonates on pregnancy and the infant","volume":"40","author":"Machairiotis","year":"2019","journal-title":"Horm Mol Biol Clin Investig"},{"key":"R51-20260916","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates","volume":"383","author":"Black","year":"2020","journal-title":"N Engl J Med"},{"key":"R52-20260916","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. FLEX Research Group","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"R53-20260916","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) [published erratum appears in J Bone Miner Res 2012;27:2612","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"key":"R54-20260916","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R55-20260916","doi-asserted-by":"crossref","first-page":"364","DOI":"10.11622\/smedj.2019028","article-title":"Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review","volume":"60","author":"Chandran","year":"2019","journal-title":"Singapore Med J"},{"key":"R57-20260916","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1210\/jc.2018-01965","article-title":"Invasive oral procedures and events in postmenopausal women with osteoporosis treated with denosumab for up to 10 years","volume":"104","author":"Watts","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R58-20260916","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"key":"R60-20260916","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1359\/JBMR.050509","article-title":"Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study","volume":"20","author":"Siris","year":"2005","journal-title":"J Bone Miner Res"},{"key":"R61-20260916","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1001\/jama.2019.5780","article-title":"Medication use for the risk reduction of primary breast cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"322","author":"Nelson","year":"2019","journal-title":"JAMA"},{"key":"R62-20260916","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/GME.0000000000000619","article-title":"Effects of ospemifene on bone parameters including clinical biomarkers in postmenopausal women","volume":"23","author":"Constantine","year":"2016","journal-title":"Menopause"},{"key":"R63-20260916","first-page":"202","article-title":"Management of menopausal symptoms. Practice Bulletin No. 141 [published errata appear in Obstet Gynecol 2018;131:604; Obstet Gynecol 2016;127:166]. American College of Obstetricians and Gynecologists","volume":"123","year":"2014","journal-title":"Obstet Gynecol"},{"key":"R64-20260916","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. Women's Health Initiative Investigators","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"key":"R65-20260916","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1359\/jbmr.060312","article-title":"Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. Women's Health Initiative Investigators","volume":"21","author":"Jackson","year":"2006","journal-title":"J Bone Miner Res"},{"key":"R66-20260916","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","article-title":"Changes in bone density and turnover after alendronate or estrogen withdrawal. Early Postmenopausal Intervention Cohort Study Group","volume":"11","author":"Wasnich","year":"2004","journal-title":"Menopause"},{"key":"R68-20260916","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.fertnstert.2009.02.093","article-title":"Efficacy of tissue-selective estrogen complex of bazedoxifene\/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women","volume":"92","author":"Lindsay","year":"2009","journal-title":"Fertil Steril"},{"key":"R69-20260916","doi-asserted-by":"crossref","first-page":"E189","DOI":"10.1210\/jc.2013-1707","article-title":"Effects of bazedoxifene\/conjugated estrogens on the endometrium and bone: a randomized trial. SMART-5 Investigators","volume":"99","author":"Pinkerton","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R71-20260916","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am J Med"},{"key":"R75-20260916","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bone.2018.10.015","article-title":"Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: results from the ACTIVE phase 3 trial","volume":"120","author":"Miller","year":"2019","journal-title":"Bone"},{"key":"R76-20260916","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11657-019-0564-7","article-title":"Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability","volume":"14","author":"McCloskey","year":"2019","journal-title":"Arch Osteoporos"},{"key":"R77-20260916","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R79-20260916","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"R80-20260916","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/13697137.2018.1433655","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials","volume":"21","author":"Liu","year":"2018","journal-title":"Climacteric"},{"key":"R81-20260916","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"R82-20260916","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study","volume":"33","author":"McClung","year":"2018","journal-title":"J Bone Miner Res"},{"key":"R83-20260916","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","article-title":"Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab","volume":"30","author":"Kendler","year":"2019","journal-title":"Osteoporos Int"},{"key":"R84-20260916","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1210\/jc.2003-030501","article-title":"The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial","volume":"89","author":"Clowes","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R85-20260916","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1007\/s00198-018-4759-3","article-title":"A systematic review of factors affecting medication adherence among patients with osteoporosis","volume":"29","author":"Yeam","year":"2018","journal-title":"Osteoporos Int"},{"key":"R86-20260916","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF) [published errata appear in Osteoporos Int 2020;31:209; Osteoporos Int 2020;31:801]","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos Int"},{"key":"R88-20260916","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00198-015-3386-5","article-title":"Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation [published erratum appears in Osteoporos Int 2016;27:2643\u20136]","volume":"27","author":"Weaver","year":"2016","journal-title":"Osteoporos Int"},{"key":"R89-20260916","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1007\/s00198-016-3699-z","article-title":"Erratum and additional analyses re: calcium plus vitamin D supplementation and the risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation","volume":"27","author":"Weaver","year":"2016","journal-title":"Osteoporos Int"},{"key":"R90-20260916","doi-asserted-by":"crossref","first-page":"e1917789","DOI":"10.1001\/jamanetworkopen.2019.17789","article-title":"Vitamin D and calcium for the prevention of fracture: a systematic review and meta-analysis","volume":"2","author":"Yao","year":"2019","journal-title":"JAMA Netw Open"},{"key":"R91-20260916","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2017.21640","article-title":"Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults: evidence report and systematic review for the US Preventive Services Task Force","volume":"319","author":"Kahwati","year":"2018","journal-title":"JAMA"},{"key":"R92-20260916","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/gme.0b013e31821fc8e0","article-title":"The role of soy isoflavones in menopausal health: report of The North American Menopause Society\/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010)","volume":"18","year":"2011","journal-title":"Menopause"},{"key":"R93-20260916","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/13697137.2016.1238451","article-title":"Effects of phytoestrogens on bone mineral density during the menopause transition: a systematic review of randomized, controlled trials","volume":"19","author":"Abdi","year":"2016","journal-title":"Climacteric"},{"key":"R94-20260916","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3945\/ajcn.116.151464","article-title":"A systematic review and meta-analysis of the effects of isoflavone formulations against estrogen-deficient bone resorption in peri- and postmenopausal women","volume":"106","author":"Lambert","year":"2017","journal-title":"Am J Clin Nutr"},{"key":"R95-20260916","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/GME.0b013e3182896ae5","article-title":"Controlled flax interventions for the improvement of menopausal symptoms and postmenopausal bone health: a systematic review","volume":"20","author":"Dew","year":"2013","journal-title":"Menopause"},{"key":"R96-20260916","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3945\/jn.115.219238","article-title":"Long-term supplementation of green tea extract does not modify adiposity or bone mineral density in a randomized trial of overweight and obese postmenopausal women","volume":"146","author":"Dostal","year":"2016","journal-title":"J Nutr"},{"key":"R97-20260916","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00198-011-1577-2","article-title":"The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis","volume":"23","author":"Zhu","year":"2012","journal-title":"Osteoporos Int"},{"key":"R98-20260916","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/08952841.2018.1418822","article-title":"The effect of protein diets in postmenopausal women with osteoporosis: systematic review of randomized controlled trials","volume":"31","author":"Koutsofta","year":"2019","journal-title":"J Women Aging"},{"key":"R99-20260916","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/nu10010097","article-title":"Specific collagen peptides improve bone mineral density and bone markers in postmenopausal women\u2013a randomized controlled study","volume":"10","author":"K\u00f6nig","year":"2018","journal-title":"Nutrients"},{"key":"R100-20260916","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/GME.0000000000001831","article-title":"Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society","volume":"28","year":"2021","journal-title":"Menopause"},{"key":"R101-20260916","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11657-013-0167-7","article-title":"Effect of a dedicated osteoporosis health professional on screening and treatment in outpatients presenting with acute low trauma non-hip fracture: a systematic review","volume":"9","author":"Bell","year":"2014","journal-title":"Arch Osteoporos"}],"updated-by":[{"DOI":"10.1097\/aog.0000000000004855","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000}}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000004730","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:04:23Z","timestamp":1789556663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000004730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004730","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"2022-01-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}